Cassava Sciences (NASDAQ:FLNA) Releases Quarterly Earnings Results

Posted by George Bondi on Jul 30th, 2026

Cassava Sciences (NASDAQ:FLNA – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.18) earnings per share for the quarter, FiscalAI reports.

Cassava Sciences Stock Performance

NASDAQ:FLNA opened at $0.87 on Thursday. Cassava Sciences has a one year low of $0.86 and a one year high of $4.98. The stock has a market cap of $42.01 million, a PE ratio of -0.54 and a beta of -0.73. The stock has a 50 day moving average price of $1.22 and a 200 day moving average price of $1.66.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on FLNA shares. Weiss Ratings restated a “sell (e+)” rating on shares of Cassava Sciences in a research report on Monday, July 20th. Wall Street Zen lowered shares of Cassava Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Finally, Maxim Group restated a “buy” rating and set a $5.00 price target on shares of Cassava Sciences in a research report on Tuesday, May 26th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Cassava Sciences has an average rating of “Hold” and an average price target of $5.00.

Check Out Our Latest Research Report on FLNA

Hedge Funds Weigh In On Cassava Sciences

Several institutional investors and hedge funds have recently bought and sold shares of FLNA. AQR Capital Management LLC acquired a new stake in shares of Cassava Sciences during the 1st quarter worth about $120,000. Goldman Sachs Group Inc. boosted its position in shares of Cassava Sciences by 77.9% during the first quarter. Goldman Sachs Group Inc. now owns 496,313 shares of the company’s stock worth $744,000 after buying an additional 217,404 shares during the period. Strs Ohio purchased a new position in shares of Cassava Sciences during the first quarter worth $178,000. Marshall Wace LLP acquired a new stake in shares of Cassava Sciences in the second quarter valued at $130,000. Finally, Jump Financial LLC acquired a new stake in shares of Cassava Sciences in the second quarter valued at $50,000. 38.05% of the stock is currently owned by institutional investors and hedge funds.

About Cassava Sciences

(Get Free Report)

Cassava Sciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies and diagnostics for Alzheimer’s disease and related neurodegenerative disorders. Headquartered in Austin, Texas, the company was originally founded as Pain Therapeutics in 1998 and rebranded to Cassava Sciences in 2017. Cassava’s research program centers on small molecules designed to address underlying mechanisms of neurodegeneration rather than solely targeting amyloid plaques or tau tangles.

The company’s lead drug candidate, simufilam (formerly PTI-125), is a proprietary small molecule that aims to restore normal shape and function to the scaffolding protein filamin A, which has been implicated in impaired neuronal signaling and inflammation in Alzheimer’s patients.